Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
|Deserunt mollit sunt Lorem laborum do id aliqua dolore||28 Nov 2018||Lorem|
|Incyte’s Phase III itacitinib sparks uncertainty on JAK1 selectivity's advantage in acute GVHD vs its JAK1/JAK2 inhibitor in sNDA review||28 Nov 2018||Mariana Lenharo|
|Gottlieb’s leadership to see cell therapies, generics hit the market faster, but budget, staffing challenges remain – experts||19 May 2017||Fiona Barry|
|Osiris’ stem cell therapy Prochymal faces reservations in Phase III Crohn’s trial – experts||01 Nov 2012||Surani Fernando|
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Insight on companies’ CRO and business development needs, strategies and relationships
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer